Back to top

Analyst Blog

CA-based medical instruments maker, Varian Medical Systems, Inc. (VAR - Analyst Report) recently revealed that its Edge radiosurgery system is capable of delivering sub-millimeter isocenter accurate doses while treating a targeted tumor. The same was substantiated by medical researchers from the Portugal-based Champalimaud Centre for the Unknown.

VAR’s Edge radiosurgery system is a fast, precise and non-invasive alternative to conventional surgery for the treatment of patients with lung, prostate, spine and brain tumors. The system allows clinicians to destroy tumors from outside the body using high-energy X-rays.

VAR’s Edge radiosurgery suite, unveiled by the company in Oct 2012, consists of many integrated subsystems for planning and delivering advanced radiosurgery treatments. It comprises patient positioning, image guidance, beam shaping, real-time tumor tracking and dose delivery systems.

While each of these systems is very precise in itself, VAR demonstrated that the system as a whole can be accurate to less than a millimeter while delivering doses. This is highly advantageous while delivering high doses to tumors near critical organs and structures within the body.

In Jan 2013, VAR’s Edge radiosurgery suite received 510(k) clearance from the U.S. Food and Drug Administration. Subsequently, in Sep 2013, Champalimaud Centre for the Unknown and Henry Ford Health System became the first institutions to install VAR’s Edge radiosurgery suite in Europe and North America, respectively.  

Researchers from the Champalimaud Centre and the Henry Ford Health System will be making seven scientific presentations about VAR’s Edge System at the American Association of Physicists in Medicine (AAPM) meeting in Austin, TX from Jul 20-24.  

Presentations by the two teams will mainly focus on early adopters’ work with VAR’s Edge radiosurgery system. The presentations will also cover a wide spectrum of clinical issues ranging from the accuracy of patient set-up for image-guided intracranial radiosurgery to methods for accurately commissioning a new Edge system.

According to the company, these teams are demonstrating superior capabilities of the Edge system while figuring out and documenting best practices for others to follow. In 2013, VAR announced its decision to launch The Edge Advisory Board, in order to partner with thought leaders in radiosurgery, including neuro- and thoracic surgeons as well as radiation oncologists, to support clinical education and advance standards of care.

Currently, VAR carries a Zacks Rank #3 (Hold). Better-ranked stocks in the medical instruments industry include Accuray Incorporated (ARAY - Analyst Report), Masimo Corporation (MASI - Analyst Report) and Heartware International Inc. (HTWR - Snapshot Report). Both Accuray and Masimo sport a Zacks Rank #1 (Strong Buy), while Heartware International carries a Zacks Rank #2 (Buy).
 

Please login to Zacks.com or register to post a comment.